NCT01331317

Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy

The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Peter Rossing · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to assess the impact of three months of treatment with an active vitamin D analogue on a risk marker for excess overall mortality and cardiovascular morbidity/mortality in Type 1 diabetic patients with diabetic kidney disease. The hypothesis is that active vitamin D analogue treatment reduces the risk of cardiovascular morbidity and mortality in patients with type 1 diabetic kidney disease.

Conditions

• Cardiovascular Disease
• Diabetic Nephropathy

Interventions

Type	Name	Description
DRUG	Paricalcitol	capsule, 1-2 micrograms daily for 90 days

Timeline

• Start date: 2010-04-01
• Primary completion: 2012-04-01
• Completion: 2012-04-01
• First posted: 2011-04-08
• Last updated: 2012-04-13

Locations

1 site across 1 country: Denmark